Recently, a novel selective capture methodology was reported for exosomes expressing the prostate-specific membrane antigen (PSMA) biomarker, critical for early diagnosis, prognosis and treatment design of prostate cancer [149]. Here, FOLH1 is linked to prostate cancer.